Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.
暂无分享,去创建一个
Catherine J. Wu | J. Ritz | S. Nikiforow | P. Armand | R. Soiffer | Jennifer R. Brown | C. Cutler | Haesook T. Kim | J. Antin | V. Ho | E. Alyea | R. Romee | C. Reynolds | J. Koreth | M. Gooptu | C. J. Shaughnessy | S. C. Rai | Carol G. Reynolds | Mahasweta Gooptu
[1] I. Schmale. European Society for Blood and Marrow Transplantation , 2020, Onkologische Welt.
[2] D. Porter,et al. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Maloney,et al. Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure. , 2020, Blood.
[4] P. Thall,et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.
[5] Brandon Galarita,et al. Chronic , 2020, Definitions.
[6] B. Cheson,et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia , 2020, British journal of haematology.
[7] A. Ho,et al. Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis , 2019, Haematologica.
[8] J. Mehta,et al. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report , 2019, Clinical Cancer Research.
[9] A. Zelenetz,et al. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. , 2019, Blood advances.
[10] G. Helbig,et al. Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience , 2019, Annals of Hematology.
[11] P. Abrisqueta,et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. , 2019, Blood.
[12] G. Mufti,et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis , 2018, Journal of internal medicine.
[13] J. Ritz,et al. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] E. Kimby,et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. , 2018, Blood.
[15] J. Gribben. How and when I do allogeneic transplant in CLL. , 2018, Blood.
[16] S. Montoto,et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report , 2018, Bone Marrow Transplantation.
[17] B. Cheson,et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis , 2018, Haematologica.
[18] S. Montoto,et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties , 2018, Bone Marrow Transplantation.
[19] Jeffrey A Jones,et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. , 2018, The Lancet. Oncology.
[20] J. Ritz,et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Byrd,et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Jeffrey A Jones,et al. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Gribben,et al. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] E. Montserrat,et al. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors? , 2016, Clinical lymphoma, myeloma & leukemia.
[25] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[26] J. Ritz,et al. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] E. Montserrat,et al. Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia? , 2015, Current Hematologic Malignancy Reports.
[28] E. Kimby,et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? , 2014, Blood.
[29] J. Ritz,et al. White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome , 2014, American journal of hematology.
[30] J. Gribben,et al. Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome , 2012, Leukemia.
[31] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[32] E. Kimby,et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus , 2007, Leukemia.
[33] M. Sorror,et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.
[34] M Schemper,et al. A Solution to the Problem of Monotone Likelihood in Cox Regression , 2001, Biometrics.
[35] A. Barrett. Mechanisms of the Graft‐versus‐Leukemia Reaction , 1997, Stem cells.
[36] D. Firth. Bias reduction of maximum likelihood estimates , 1993 .
[37] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[38] H. Akaike. A new look at the statistical model identification , 1974 .